

Table S1. Incidence of irAEs according to the measurement of FDG uptake and TB

All patients (n=85)	Any irAEs Yes / No (39 / 46)	<i>p</i> -value	Grade 3 or 4 irAEs Yes / No (9 / 76)	<i>p</i> -value
Gender				
Male (n=65)	33 / 32	0.12	6 / 59	0.43
Female (n=20)	6 / 14		3 / 17	
TLG				
High (n=59)	22 / 37	0.02	4 / 55	0.12
Low (n=26)	17 / 9		5 / 21	
MTV				
High (n=58)	22 / 36	0.01	5 / 53	0.44
Low (n=27)	17 / 10		4 / 23	
SUV _{max}				
High (n=52)	21 / 31	<0.01	5 / 47	0.27
Low (n=33)	18 / 15		4 / 29	
TB				
High (n=13)	7 / 5	0.53	2 / 11	0.62
Low (n=72)	30 / 42		7 / 65	

Abbreviations: TLG, total lesion glycolysis; MTV, metabolic tumor volume; SUV_{max}, the maximum of standardized uptake value; TB, tumor burden; irAEs, immune-related adverse events.